Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 874-880

  Siegel, David ^a   Shieh, Biehuoy ^a   Yan, Chao ^a   Kepa, Jadwiga K ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 (ALLYLAMINO) 17 DEMETHOXYGELDANAMYCIN HYDROQUINONE; DRUG METABOLITE; HEAT SHOCK PROTEIN 90; INDOLE DERIVATIVE; MANGANESE SUPEROXIDE DISMUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SUPEROXIDE DISMUTASE; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CYCLE ARREST; CELL LEVEL; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; OXYGEN CONSUMPTION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REDUCTION; STABLE TRANSFECTION;

BENZOQUINONES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NAD(P)H DEHYDROGENASE (QUINONE); PANCREATIC NEOPLASMS; SUPEROXIDE DISMUTASE;

EID: 79951993000     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176438     Document Type: Article

References (38)

1. Banerji U, Affolter A, Judson I, Marais R, and Workman P (2008) BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7:737-739. (Pubitemid 351551026)
2. Benson AM, Hunkeler MJ, and Talalay P (1980) Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77:5216-5220. (Pubitemid 11195538)
3. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, et al. (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984-8995.
4. Boothman DA, Meyers M, Fukunaga N, and Lee SW (1993) Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells. Proc Natl Acad Sci USA 90:7200-7204. (Pubitemid 23222417)
5. Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, Griffin RJ, Lim BU, Kim JS, Lee DS, et al. (2007) Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive β-lapachone on cancer cells. Neoplasia 9:634-642. (Pubitemid 47328082)
6. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, and Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686-10691.
7. Douglas M, Lim AR, Porter JR, West K, Pink MM, Ge J, Wylie AA, Tibbits TT, Biggs K, Curtis M, et al. (2009) The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo. Mol Cancer Ther 8:3369-3378.
8. Ernster L (1967) DT-diaphorase. Methods Enzymol 10:309-317.
9. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, and Workman P (2009) Acquired resistance to 17-allylamino-17- demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 69:1966-1975.
10. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, and Ross D (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H: quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65:10006-10015. (Pubitemid 41541482)
11. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, and Ross D (2006) The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 70:1194-1203. (Pubitemid 44435970)
12. Guo W, Siegel D, and Ross D (2008) Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. J Pharm Sci 97:5147-5157.
13. Hanson BE and Vesole DH (2009) Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs 18:1375-1383.
14. Kelland LR, Sharp SY, Rogers PM, Myers TG, and Workman P (1999) DTDiaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940-1949.
15. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, and Cullen JJ (2005) Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 43:215-224. (Pubitemid 41134429)
16. Lin PS, Ho KC, Sung SJ, and Tsai S (1993) Cytotoxicity and manganese superoxide dismutase induction by tumor necrosis factor-alpha and ionizing radiation in MCF-7 human breast carcinoma cells. Lymphokine Cytokine Res 12:303-308. (Pubitemid 23305113)
17. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
18. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shirai M, and Kubota N (2005) Heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 96:911-917. (Pubitemid 43056131)
19. Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, Jones WJ, Barnakova LA, Koblish HK, Todd MJ, et al. (2006) Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 45:5678-5685. (Pubitemid 43673198)
20. McCollum AK, Teneyck CJ, Sauer BM, Toft DO, and Erlichman C (2006) Upregulation of heat shock protein 27 induces resistance to 17- allylaminodemethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 66:10967-10975. (Pubitemid 44876996)
21. McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, and Erlichman C (2008) P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 68:7419-7427.
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
23. Russell JS, Burgan W, Oswald KA, Camphausen K, and Tofilon PJ (2003) Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9:3749-3755. (Pubitemid 37169244)
24. Schlager JJ and Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45:403-409. (Pubitemid 20087182)
25. Siegel D and Ross D (2000) Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246-253.
26. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, and Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol 59:263-268. (Pubitemid 32108559)
27. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, and Ross D (2004) NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 65:1238-1247. (Pubitemid 38543494)
28. Siegel D, McGuinness SM, Winski SL, and Ross D (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9:113-121. (Pubitemid 29176730)
29. Siegel D, Reigan P, Guo W, and Ross D (2007) The metabolism of anti-tumor quinones by NRH:quinone oxidoreductase 2 (NQO2), in Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 April 14-18; Los Angeles, CA. Abstract 1499. American Association for Cancer Research, Philadelphia, PA.
30. Supko JG, Hickman RL, Grever MR, and Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315.
31. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, et al. (2006) Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103:17408-17413. (Pubitemid 44788982)
32. Taldone T, Sun W, and Chiosis G (2009) Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 17:2225-2235.
33. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, and Myles DC (2004) Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 12:5317-5329. (Pubitemid 39243952)
34. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, and Gibson NW (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DTdiaphorase activity and mitomycin sensitivity. Cancer Res 52:797-802.
35. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, and Ross D (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75:69-75. (Pubitemid 27007275)
36. Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, and Ross D (2001) Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry 40:15135-15142. (Pubitemid 33151928)
37. Wong GH (1995) Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim Biophys Acta 1271:205-209.
38. Zhang H, Neely L, Lundgren K, Yang YC, Lough R, Timple N, and Burrows F (2010) BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer 126:1226-1234.